Literature DB >> 20628718

[Progressive dyspnoea in two patients with carcinoid syndrome].

S Nölting1, M Nicolaus, J Behr, R Baumgartner, H Mete, P Boekstegers, K Herrmann, D Theisen, M Lehrke, B Göke, J Schirra, C J Auernhammer.   

Abstract

In patients with carcinoid syndrome, there has always to be considered cardiac impairment. We report about two patients with hepatic and bone metastases of a neuroendocrine tumor of the midgut, who suffered from progressive dyspnea. This was caused in both cases by a right-to-left atrial shunt, in case 1 based on a patent foramen ovale (PFO), in case 2 based on a secundum atrial septal defect. Symptoms were significantly reduced by percutaneous closure of PFO and ASD, respectively. Right-to-left atrial shunt was facilitated by right-sided carcinoid induced endocardial fibrosis with the consequence of severe tricuspid regurgitation, leading to an increase of right atrial pressure.

Entities:  

Mesh:

Year:  2010        PMID: 20628718     DOI: 10.1007/s00108-010-2649-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

1.  Diagnosis of patent foramen ovale using contrast-enhanced dynamic MRI: a pilot study.

Authors:  Oliver K Mohrs; Steffen E Petersen; Damir Erkapic; Christine Rubel; Rainer Schräder; Bernd Nowak; W Andreas Fach; Hans-Ulrich Kauczor; Thomas Voigtlaender
Journal:  AJR Am J Roentgenol       Date:  2005-01       Impact factor: 3.959

2.  Cardiac magnetic resonance imaging and transesophageal echocardiography in patients with transcatheter closure of patent foramen ovale.

Authors:  Thorsten Nusser; Martin Höher; Nico Merkle; Olaf C Grebe; Jochen Spiess; Hans A Kestler; Volker Rasche; Matthias Kochs; Vinzenz Hombach; Jochen Wöhrle
Journal:  J Am Coll Cardiol       Date:  2006-06-23       Impact factor: 24.094

3.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology.

Authors:  Leslie T Cooper; Kenneth L Baughman; Arthur M Feldman; Andrea Frustaci; Mariell Jessup; Uwe Kuhl; Glenn N Levine; Jagat Narula; Randall C Starling; Jeffrey Towbin; Renu Virmani
Journal:  Eur Heart J       Date:  2007-10-24       Impact factor: 29.983

4.  Profound hypoxaemia corrected by PFO closure device in carcinoid heart disease.

Authors:  Philip M Mottram; David J McGaw; Ian T Meredith; Roger E Peverill; Richard W Harper
Journal:  Eur J Echocardiogr       Date:  2008-01

5.  Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome.

Authors:  A Hussain; E T Young; J D Greaves; P J Hammond; J M Hughes; S C Wallis; S R Bloom
Journal:  Clin Endocrinol (Oxf)       Date:  1994-10       Impact factor: 3.478

6.  Dynamic contrast-enhanced MRI before and after transcatheter occlusion of patent foramen ovale.

Authors:  Oliver K Mohrs; Steffen E Petersen; Damir Erkapic; Anja Victor; Thomas Schlosser; Bernd Nowak; Guenter Kauffmann; Thomas Voigtlaender; Hans-Ulrich Kauczor
Journal:  AJR Am J Roentgenol       Date:  2007-03       Impact factor: 3.959

Review 7.  The significance of patent foramen ovale: a current review of associated conditions and treatment.

Authors:  Magnus C Johansson; Peter Eriksson; Mikael Dellborg
Journal:  Int J Cardiol       Date:  2009-02-20       Impact factor: 4.164

8.  Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.

Authors:  P A Pellikka; A J Tajik; B K Khandheria; J B Seward; J A Callahan; H C Pitot; L K Kvols
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

9.  Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.

Authors:  Nicolas Mansencal; Emmanuel Mitry; Rémy Pillière; Céline Lepère; Benoît Gérardin; Jérôme Petit; Iradj Gandjbakhch; Philippe Rougier; Olivier Dubourg
Journal:  Am J Cardiol       Date:  2008-02-11       Impact factor: 2.778

10.  Severe intrapulmonary shunting associated with metastatic carcinoid.

Authors:  D F Lee; L S Lepler
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.